{"transactions":[{"id":729977,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:09:10.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":20275,"derivative":{"exercise_price":1.52,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-26-003033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826003033/form4.xml","form_type":"4"}},{"id":769403,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:33:47.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":9366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the RSUs for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs and underlying common stock."}],"balance_after":9366,"source":{"system":"sec-edgar","filing":"0000905148-26-002558","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514826002558/form4.xml","form_type":"4"}},{"id":890110,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-02-21T00:47:02.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 12 substantially equal monthly installments following the date of grant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the RSUs and options for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs or option and underlying common stock, as applicable."}],"balance_after":8300,"derivative":{"exercise_price":28.06,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001933414-26-000039","document":"wk-form4_1771634819.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1792061/000193341426000039/wk-form4_1771634819.xml","form_type":"4"}},{"id":890109,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-21T00:47:02.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":6200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units (\"RSUs\") are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the RSUs and options for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus III Fund, L.P. (the \"Nexus Fund III\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the RSUs or option and underlying common stock, as applicable."}],"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001933414-26-000039","document":"wk-form4_1771634819.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1792061/000193341426000039/wk-form4_1771634819.xml","form_type":"4"}},{"id":1011159,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:11:51.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-01","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0001193125-25-259038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259038/ownership.xml","form_type":"4"}},{"id":1011158,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:11:51.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0001193125-25-259038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259038/ownership.xml","form_type":"4"}},{"id":1011157,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:11:51.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001193125-25-259038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259038/ownership.xml","form_type":"4"}},{"id":1011156,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:11:51.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.64,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-259038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259038/ownership.xml","form_type":"4"}},{"id":1011155,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:11:51.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), and RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":24.16,"expiration_date":"2031-04-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-25-259038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259038/ownership.xml","form_type":"4"}},{"id":1011154,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:11:51.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), and RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":24.29,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001193125-25-259038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259038/ownership.xml","form_type":"4"}},{"id":1011153,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-30T20:11:51.000Z","date":"2025-10-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 17, 2025, by and among 89bio, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $14.50 per Share in cash, without interest (the \"Closing Amount\") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an \"Out of the Money Option\"), [continues to Footnote 4]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"[Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":21.4,"expiration_date":"2030-04-05","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001193125-25-259038","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000119312525259038/ownership.xml","form_type":"4"}},{"id":1107237,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-17T22:04:32.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":20275,"derivative":{"exercise_price":1.2,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-25-002177","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514825002177/form4.xml","form_type":"4"}},{"id":1248792,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-02-24T23:59:12.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":32900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 substantially equal monthly installments following the date of grant."}],"balance_after":32900,"derivative":{"exercise_price":10.2,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":32900},"source":{"system":"sec-edgar","filing":"0001933414-25-000016","document":"wk-form4_1740441546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1792061/000193341425000016/wk-form4_1740441546.xml","form_type":"4"}},{"id":1281331,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T16:01:10.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":56400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":56400,"derivative":{"exercise_price":9.6,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":56400},"source":{"system":"sec-edgar","filing":"0000950170-25-014436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000095017025014436/ownership.xml","form_type":"4"}},{"id":1470266,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T21:27:30.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":20275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through each applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":20275,"derivative":{"exercise_price":6.52,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":20275},"source":{"system":"sec-edgar","filing":"0000905148-24-001775","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000090514824001775/form4.xml","form_type":"4"}},{"id":1501441,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-24T23:52:50.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":17500,"derivative":{"exercise_price":4.88,"expiration_date":"2034-05-23","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-24-064848","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000095017024064848/ownership.xml","form_type":"4"}},{"id":1503118,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-05-23T20:22:37.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting."}],"balance_after":22000,"derivative":{"exercise_price":12.52,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001933414-24-000023","document":"wk-form4_1716495741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1792061/000193341424000023/wk-form4_1716495741.xml","form_type":"4"}},{"id":1658039,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T20:17:36.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":45150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 45,150 shares of the Issuer's Common Stock, which will vest in full on February 1, 2025, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":45150,"derivative":{"exercise_price":9.98,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":45150},"source":{"system":"sec-edgar","filing":"0000950170-24-011476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000095017024011476/ownership.xml","form_type":"4"}},{"id":1844819,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:52:15.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":13200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 21, 2023. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":13200,"derivative":{"exercise_price":2.81,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":13200},"source":{"system":"sec-edgar","filing":"0000899243-23-016379","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924323016379/doc4.xml","form_type":"4"}},{"id":1854537,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T19:53:23.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":22383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":22383,"derivative":{"exercise_price":14.77,"exercise_date":"2024-06-13","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":22383},"source":{"system":"sec-edgar","filing":"0001209191-23-037588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919123037588/doc4.xml","form_type":"4"}},{"id":2019307,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-14T02:03:24.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 36 monthly installments beginning on March 9, 2023."}],"balance_after":44000,"derivative":{"exercise_price":16,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001628280-23-003430","document":"wf-form4_167634018923335.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1792061/000162828023003430/wf-form4_167634018923335.xml","form_type":"4"}},{"id":2019308,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-13T17:30:19.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":27400,"derivative":{"exercise_price":14.7,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0000899243-23-004787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924323004787/doc4.xml","form_type":"4"}},{"id":2114022,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-17T02:05:37.000Z","date":"2022-11-14","kind":"grant","acquired":true,"shares":35235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in 36 equal monthly installments starting on October 12, 2022 (\"Vesting Commencement Date\"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":35235,"derivative":{"exercise_price":12.5,"expiration_date":"2032-11-13","underlying":"Common Stock","underlying_shares":35235},"source":{"system":"sec-edgar","filing":"0001209191-22-057421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000120919122057421/doc4.xml","form_type":"4"}},{"id":2236218,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T19:48:48.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":17538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":17538,"derivative":{"exercise_price":18.78,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":17538},"source":{"system":"sec-edgar","filing":"0001209191-22-036135","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000120919122036135/doc4.xml","form_type":"4"}},{"id":2243542,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-03T20:42:22.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 1, 2022. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":11600,"derivative":{"exercise_price":3.43,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":11600},"source":{"system":"sec-edgar","filing":"0000899243-22-020988","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924322020988/doc4.xml","form_type":"4"}},{"id":2265088,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-18T16:09:41.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-018588","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924322018588/doc4.xml","form_type":"4"}},{"id":2661416,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T20:23:43.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":16608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":0,"derivative":{"exercise_price":26.03,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":16608},"source":{"system":"sec-edgar","filing":"0000899243-21-025141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924321025141/doc4.xml","form_type":"4"}},{"id":2729231,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-04T20:31:42.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":23200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 30, 2021. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":23200,"derivative":{"exercise_price":16,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":23200},"source":{"system":"sec-edgar","filing":"0000899243-21-018118","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785530/000089924321018118/doc4.xml","form_type":"4"}},{"id":2744632,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-19T16:49:42.000Z","date":"2021-04-15","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, one third of which will vest on April 15, 2022, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to the Reporting Person's continued service to the Issuer through each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), and RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":12500,"derivative":{"exercise_price":24.16,"expiration_date":"2031-04-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000899243-21-016232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924321016232/doc4.xml","form_type":"4"}},{"id":3002285,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-21T16:58:27.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":16608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This amendment is being filed solely for the purpose of correcting the vesting schedule, as follows: this stock option shall vest on the earlier of (i) the first anniversary of the grant date or (ii) the Company's next annual meeting of stockholders following the grant date, subject to continued service through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2030-07-23","underlying":"Common Stock","underlying_shares":16608},"source":{"system":"sec-edgar","filing":"0000899243-20-028906","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924320028906/doc4a.xml","form_type":"4/A","original_submission_date":"2020-07-24"}},{"id":3076294,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-24T19:19:42.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":16608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest over 3 years, with 1/3 vesting on July 23, 2021 and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2030-07-23","underlying":"Common Stock","underlying_shares":16608},"source":{"system":"sec-edgar","filing":"0000899243-20-020435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808865/000089924320020435/doc4.xml","form_type":"4"}},{"id":3083242,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-14T17:00:59.000Z","date":"2020-06-22","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 7,000 shares of the Issuer's Common Stock, which will vest in full on June 22, 2021, subject to the Reporting Person's continued service to the Issuer through such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":7000,"derivative":{"exercise_price":24.29,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-20-019088","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924320019088/doc4.xml","form_type":"4"}},{"id":3180165,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":36206,"kind":"person","name":"DiRocco Derek","position":1,"cik":"0001792061","reported_name":"DiRocco Derek","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-07T16:21:29.000Z","date":"2020-04-05","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 7,000 shares of the Issuer's Common Stock, one third of which will vest on April 5, 2021, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":7000,"derivative":{"exercise_price":21.4,"expiration_date":"2030-04-05","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-20-010411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1785173/000089924320010411/doc4.xml","form_type":"4"}}]}